UROGEN PHARMA LTD
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 201
- Market Cap
- -
- Website
- http://www.urogen.com
Clinical Trials
19
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (17 trials with phase data)• Click on a phase to view related trials
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
- Conditions
- Upper Urinary Tract Urothelial CarcinomaUrothelial Carcinoma
- Interventions
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- UroGen Pharma Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06774131
- Locations
- 🇺🇸
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
A Phase 3 Single-arm Study of UGN-103 for the Treatment of LG IR NMIBC.
- Conditions
- Nonmuscle Invasive Bladder Cancer
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Urogen Pharma Ltd.
- Target Recruit Count
- 57
- Registration Number
- 2023-507261-25-00
- Locations
- 🇧🇬
University Multiprofessional Hospital For Active Treatment Plovdiv AD, Plovdiv, Bulgaria
🇧🇬Multiprofile Hospital For Active Treatment Dr. Tota Venkova AD, Gabrovo, Bulgaria
🇧🇬University Multiprofile Hospital For Active Treatment And Emergency Medicine N I Pirogov, Sofiya, Bulgaria
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
- Conditions
- Urothelial CarcinomaUrothelial Carcinoma Ureter RecurrentUrothelial Carcinoma of the Renal Pelvis and UreterUrothelial Carcinoma RecurrentUrothelial Carcinoma UreterUrothelial Cancer of Renal PelvisTransitional Cell Carcinoma of Renal PelvisCarcinoma, Transitional Cell
- Interventions
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- UroGen Pharma Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT05874921
- Locations
- 🇺🇸
Providence St. Johns Health Center, Santa Monica, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸Mount Sinai Medical Center of Florida, Inc., Miami, Florida, United States
Named Patient Program for Mitomycin for Pyelocalyceal Solution
- Conditions
- Urothelial Cancer of Renal PelvisUrothelial Carcinoma of the Renal Pelvis and UreterUrothelial Carcinoma UreterUrothelial Carcinoma Ureter RecurrentUrothelial CarcinomaUrothelial Carcinoma Recurrent
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- UroGen Pharma Ltd.
- Registration Number
- NCT05494411
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
- Conditions
- Non-muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2025-05-26
- Lead Sponsor
- Urogen Pharma Ltd.
- Target Recruit Count
- 48
- Registration Number
- 2023-508404-37-00
- Locations
- 🇮🇹
IRCCS Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
🇮🇹Ospedale San Raffaele S.r.l., Milan, Italy
🇪🇸Hospital Universitario Hm Sanchinarro, Madrid, Spain
- Prev
- 1
- 2
- 3
- 4
- Next
News
UGN-102 Shows Durable Response in Low-Grade Bladder Cancer Trial
• The ENVISION trial results, published in the _Journal of Urology_, demonstrate an 82.3% duration of response at 12 months in patients treated with UGN-102 who achieved complete response. • UGN-102 showed a 79.6% complete response rate at three months in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC). • UroGen's NDA for UGN-102 has been accepted by the FDA, with a PDUFA goal date of June 13, 2025, potentially offering a non-surgical option for LG-IR-NMIBC.
FDA Accepts UroGen's NDA for UGN-102 in Low-Grade Bladder Cancer
The FDA has accepted UroGen's New Drug Application (NDA) for UGN-102 (mitomycin) for intravesical solution, a potential first-in-class treatment.